ALSUntangled #70: caffeine

Jessica Hatch,Paul Barkhaus,Benjamin Barnes,Morgan Beauchamp,Michael Benatar,Tulio Bertorini,Robert Bowser,Mark Bromberg,Andrew Brown,Javier Mascias Cadavid,Gregory T Carter,Nicholas Cole,Jesse Crayle,Mazen Dimachkie,David Ennist,Eva Feldman,Timothy Fullam,Terry Heiman-Patterson,Sartaj Jhooty,Todd Levine,Xiaoyan Li,Isaac Lund,Elise Mallon,Nicholas Maragakis,Christopher McDermott,Gary Pattee,Kaitlyn Pierce,Dylan Ratner,Kim Staats,Paul Wicks,Martina Wiedau,Richard Bedlack
DOI: https://doi.org/10.1080/21678421.2023.2220742
2023-06-08
Abstract:ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here, we review caffeine which has plausible mechanisms for slowing ALS progression. However, pre-clinical studies are contradictory, and a large case series showed no relationship between caffeine intake and ALS progression rate. While low doses of caffeine are safe and inexpensive, higher doses can cause serious side effects. At this time, we cannot endorse caffeine as a treatment to slow ALS progression.
What problem does this paper attempt to address?